<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="466">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05155085</url>
  </required_header>
  <id_info>
    <org_study_id>AK002-018</org_study_id>
    <nct_id>NCT05155085</nct_id>
  </id_info>
  <brief_title>A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis</brief_title>
  <acronym>ATLAS</acronym>
  <official_title>A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Lirentelimab in Adult Subjects With Moderate-to-Severe Atopic Dermatitis Inadequately Controlled by Topical Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allakos, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allakos, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to&#xD;
      evaluate the efficacy and safety of subcutaneous lirentelimab (AK002), given monthly for 4&#xD;
      doses, in adult subjects with moderate-to-severe AD inadequately controlled by topical&#xD;
      treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects who achieve an IGA score of 0 or 1 and a reduction of ≥2 points on a 0-4 IGA scale</measure>
    <time_frame>Week 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare efficacy of lirentelimab with placebo in subjects with moderate-to-severe AD as estimated by the proportion of subjects who achieve EASI-75</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with improvement of pruritus numeric rating scale (NRS) ≥4</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>SC 150 mg of lirentelimab (AK002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive 4 monthly doses of 150 mg of lirentelimab (AK002) administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC 450 mg of lirentelimab (AK002)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive 4 monthly doses of 450 mg of lirentelimab (AK002) administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK002</intervention_name>
    <description>Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1)monoclonal antibody directed against Siglec-8</description>
    <arm_group_label>SC 150 mg of lirentelimab (AK002)</arm_group_label>
    <arm_group_label>SC 450 mg of lirentelimab (AK002)</arm_group_label>
    <other_name>Lirentelimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provided written informed consent.&#xD;
&#xD;
          2. Male or female aged ≥18 and ≤80 years at the time of signing the informed consent&#xD;
             form.&#xD;
&#xD;
          3. Chronic AD (according to the American Academy of Dermatology Consensus Criteria)&#xD;
             (Eichenfield, 2014) that has been present for at least 3 years before the screening&#xD;
             visit.&#xD;
&#xD;
          4. Documented recent history of inadequate response to treatment with topical medications&#xD;
             such as topical corticosteroids, calcineurin inhibitors, or crisaborole for at least 4&#xD;
             weeks in the 6 months prior to screening, or subjects for whom these topical&#xD;
             treatments are otherwise medically inadvisable (e.g., because of side effects or&#xD;
             safety risks).&#xD;
&#xD;
          5. EASI score of ≥16 at screening and at baseline.&#xD;
&#xD;
          6. Involvement of at least 10% or more of BSA at screening and at baseline.&#xD;
&#xD;
          7. An IGA score of 3 or above on a scale from 0-4 at screening and at baseline.&#xD;
&#xD;
          8. The subject should have applied a stable dose of non-medicated, non-prescription,&#xD;
             topical emollient at least twice daily for 7 consecutive days immediately before the&#xD;
             baseline visit.&#xD;
&#xD;
          9. Willing to apply a stable dose of non-medicated, non-prescription, topical emollient,&#xD;
             as recommended by the Investigator at least twice daily, if not already on an&#xD;
             emollient at the time of screening.&#xD;
&#xD;
         10. Commitment to remain on the same dose(s) of AD medication(s), including topical&#xD;
             emollients for the entire duration of study participation unless dose modification is&#xD;
             due to unforeseen medical necessity.&#xD;
&#xD;
         11. Willing and able to comply with the study procedures and visit schedule including&#xD;
             follow-up visits.&#xD;
&#xD;
         12. Negative screening ova and parasite test.&#xD;
&#xD;
         13. Female subjects must be either postmenopausal for at least 1 year with FSH level &gt;40&#xD;
             mIU/mL at screening or surgically sterile (tubal ligation, hysterectomy, or bilateral&#xD;
             oophorectomy) for at least 3 months, or if of childbearing potential, have a negative&#xD;
             pregnancy test and agree to use dual methods of contraception or abstain from sexual&#xD;
             activity from screening until the end of the study or for 120 days following the last&#xD;
             dose of study drug, whichever is longer.&#xD;
&#xD;
         14. Male subjects with female partners of childbearing potential must agree to use a&#xD;
             highly effective method of contraception from screening until the end of the study or&#xD;
             for 120 days following the last dose of study drug, whichever is longer. All fertile&#xD;
             men with female partners of childbearing potential should be instructed to contact the&#xD;
             Investigator immediately if they suspect their partner might be pregnant (e.g., missed&#xD;
             or late menstrual period) at any time during study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity to any constituent of the study drug.&#xD;
&#xD;
          2. Current use of biologics for any indication.&#xD;
&#xD;
          3. Any exposure to dupilumab for any condition during the subject's lifetime.&#xD;
&#xD;
          4. Anticipated use of topical or oral corticosteroids, calcineurin inhibitors, or&#xD;
             crisaborole starting at the screening visit and during the entire course of the study.&#xD;
&#xD;
          5. Treatment with any immunosuppressive or immunomodulatory drugs that may interfere with&#xD;
             the study interpretation within 12 weeks prior to the screening visit.&#xD;
&#xD;
          6. Treatment with chemotherapy or radiotherapy in the preceding 6 months.&#xD;
&#xD;
          7. Presence of skin comorbidities/concomitant conditions that may interfere with study&#xD;
             assessments or interpretation of study results.&#xD;
&#xD;
          8. Any disease or condition (medical or surgical) that in the opinion of the Investigator&#xD;
             would place the subject at increased risk.&#xD;
&#xD;
          9. History of malignancy except carcinoma in situ in the cervix, early stage prostate&#xD;
             cancer, or non-melanoma skin cancers.&#xD;
&#xD;
         10. Any disease, condition (medical or surgical), or cardiac abnormality that in the&#xD;
             opinion of the Investigator would place the subject at increased risk.&#xD;
&#xD;
         11. A helminth parasitic infection diagnosed within 6 months prior to the date informed&#xD;
             consent is obtained that has not been treated with or has failed to respond to&#xD;
             standard-of-care therapy.&#xD;
&#xD;
         12. Evidence of active hepatitis B or C at screening based on serology.&#xD;
&#xD;
         13. Evidence of active HIV infection at screening based on serology.&#xD;
&#xD;
         14. Women who are pregnant, breastfeeding, or planning to become pregnant while&#xD;
             participating in the study.&#xD;
&#xD;
         15. Presence of an abnormal screening laboratory value considered to be clinically&#xD;
             significant by the Investigator.&#xD;
&#xD;
         16. Known or suspected history of alcohol, drug, or other substance abuse or dependence&#xD;
             that, in the opinion of the Investigator, may interfere with study participation or&#xD;
             assessments.&#xD;
&#xD;
         17. Prior exposure to lirentelimab or known hypersensitivity to any constituent of the&#xD;
             study drug.&#xD;
&#xD;
         18. Participation in a concurrent interventional study with the last intervention&#xD;
             occurring within 30 days prior to study drug administration (or 90 days or 5&#xD;
             half-lives, whichever is longer, for biologic products).&#xD;
&#xD;
         19. Any other reason that in the opinion of the Investigator or the Medical Monitor makes&#xD;
             the subject unsuitable for enrollment.&#xD;
&#xD;
         20. Vaccination with live attenuated vaccines within 30 days prior to initiation of&#xD;
             treatment in the study, during the treatment period, or vaccination expected within 5&#xD;
             half-lives (4 months) of study drug administration.&#xD;
&#xD;
        This exclusion criterion does not apply to all types and formulations of vaccines&#xD;
        (including live attenuated vaccines) currently authorized by FDA or other regulatory&#xD;
        authority for the prevention of COVID-19, which may be administered before, during, or&#xD;
        after the study.&#xD;
&#xD;
        The vaccine should not be administered within 7 days before and within 7 days after the&#xD;
        administration of lirentelimab so that any side effects caused by either of the 2&#xD;
        medications can be more easily determined.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Paterson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Allakos, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig Paterson, MD</last_name>
    <phone>650-597-5002</phone>
    <email>info@allakos.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Center of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arizona Allergy and Immunology</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Research of Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>First OC Dermatology</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology Clinical Research</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peninsula Research</name>
      <address>
        <city>Rolling Hills</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Raffi Tachdjian MD, Inc</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western States Clinical</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New England Research</name>
      <address>
        <city>Shelton</city>
        <state>Connecticut</state>
        <zip>06484</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Brandon</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dolphin Medical</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FXM Clinical Research</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Research Center of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Trials of Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affinity Clinical</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lakeside Dermatology</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brock Clinical</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Continental Clinical</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skin Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Las Vegas Clinical Trials</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHEAR Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28777</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bernstein Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unity Clinical</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paddington Testing</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Galen Dermatology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skin DC</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dominion Medical</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Allergy and Asthma</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Central Contact Person</last_name>
      <phone>650-597-5002</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 1, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>December 10, 2021</last_update_submitted>
  <last_update_submitted_qc>December 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AD</keyword>
  <keyword>Dermatitis</keyword>
  <keyword>Eczema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

